Vaccination scheme for CMU recipient’s girls and non-CMU recipient’s girls.

<p>a: Rates of CMU recipients in the vaccinated population (at least one dose, dark grey) and general population (light grey). b: Percentage of vaccinated girls reimbursed for 1, 2, and 3 or more doses in 2012 and 2013 with first dose reimbursed in 2012, in CMU recipients (up) and non-CMU recipients (down).</p

Vaccination rates according to the 8 departments of the Ile-de-France region, France.

<p>Vaccination rates according to the 8 departments of the Ile-de-France region, France.</p

Determinants of geographic inequalities in HPV vaccination in the most populated region of France - Fig 4

<p>Correlations between the vaccination rate (initiation) in each of the 8 departments and the medical density (a), urbanization rate (b), average incomes per capita (c), unemployment rate (d), percentage of immigrants (e), percentage of foreigners (f), average CMU recipient rates (g) and median amount of medical consumption from 2011 to 2013 (h). Each dot corresponds to a department. a. <i>Data from the French National Medical Council (7)</i>. <i>b</i>. <i>Data from the SENAT (8)</i>. <i>c</i>. <i>Data from INSEE (9)</i>. <i>d</i>. <i>Data from INSEE (10)</i>. <i>e</i>. <i>Data from INSEE (11)</i>. <i>f</i>. <i>Data from INSEE (12)</i>. <i>g</i>. <i>Date from CMU (13)</i>. <i>h</i>. <i>Data from our database</i>.</p

Individual and obstetrical characteristics of the women included in the study (n = 481).

<p>Individual and obstetrical characteristics of the women included in the study (n = 481).</p

Risk of preterm birth within 48 hours: Optimal threshold determination.

<p><b>On the left: In cohort 1</b>: To determine the best preterm risk threshold (minimization of false-negative and false-positive rates), one reliable statistical tool was used: MinROCdist. MinROCdist is the cut-off that minimizes the distance between the ROC curve and the upper left corner of the unit square. <b><i>On the right</i>: <i>In cohort 2</i>:</b> To determine the best preterm risk threshold (minimization of false-negative and false-positive rates), one reliable statistical tool was used: MinROCdist. MinROCdist is the cut-off that minimizes the distance between the ROC curve and the upper left corner of the unit square.</p

Performance of the eight molecular signatures

<p>(A)Breast Cancer Specific Survival (Kaplan Meier curves) (B) Discrimination performances (ROC curves)</p

Concordance of the prediction with molecular signatures combination.

<p><b>Combination of 2 to 7 molecular signatures.</b> (A)Overall population (B) NPI risk groups.</p

Clinical, histological and molecular signatures of 769 ER-positive HER2-negative patients presenting breast carcinoma^*.

<p>Clinical, histological and molecular signatures of 769 ER-positive HER2-negative patients presenting breast carcinoma<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0148957#t001fn001" target="_blank">^*</a>.</p

Characteristics of the 45 studies included in our review.

<p>(Data presented as number of studies; %)</p><p>^<b>1.</b><b>Potentially life-threatening gynaecological emergency;</b></p><p>^<b>2.</b><b>Adnexal torsion;</b></p><p>^<b>3.</b><b>Haemoperitoneum;</b></p><p>^<b>4.</b><b>Complicated ectopic pregnancy;</b></p><p>^<b>5.</b><b>Complicated pelvic inflammatory disease;</b></p><p>^<b>6.</b><b>TVUS = transvaginal ultrasound;</b></p><p>^<b>7.</b><b>TAUS = transabdominal ultrasound</b></p><p>Characteristics of the 45 studies included in our review.</p

Methodological quality graph.

<p>Our judgements for each methodological quality item are presented as percentages for all included studies.</p